Early Access

10-QPeriod: Q2 FY2020

SYNOPSYS INC Quarterly Report for Q2 Ended Apr 30, 2020

Filed May 22, 2020For Securities:SNPS

Summary

Synopsys, Inc. (SNPS) reported a solid performance for the quarter ending April 30, 2020, with total revenue increasing by 3% year-over-year to $861.3 million. This growth was primarily driven by strong performance in its time-based products and the Software Integrity segment, indicating continued demand for its electronic design automation (EDA) and software security solutions. Despite the global economic uncertainties brought on by the COVID-19 pandemic, Synopsys demonstrated resilience. The company maintained healthy operating income, up 9% year-over-year, and healthy cash flow from operations. While some segments experienced minor disruptions, the company's diversified business model and its revenue recognition policy for software licenses over the arrangement period have helped to mitigate immediate impacts. Management expressed confidence in its ability to meet its liquidity needs and navigate the evolving economic landscape.

Financial Statements
Beta
Revenue$861.33M
Cost of Revenue$184.26M
Gross Profit$677.06M
R&D Expenses$302.57M
Operating Expenses$551.17M
Operating Income$125.89M
Interest Expense$1.85M
Net Income$109.92M
EPS (Basic)$0.73
EPS (Diluted)$0.71
Shares Outstanding (Basic)150.60M
Shares Outstanding (Diluted)154.38M

Key Highlights

  • 1Total revenue for the three months ended April 30, 2020, increased by 3% to $861.3 million compared to the prior year.
  • 2Operating income grew by 9% year-over-year to $125.9 million.
  • 3Time-based products revenue saw a 6% increase, highlighting consistent demand for core offerings.
  • 4The Software Integrity segment revenue grew by 6% for the quarter, demonstrating expansion in the software security and quality market.
  • 5Cash provided by operating activities for the six months ended April 30, 2020, significantly increased by $180.9 million to $389.7 million.
  • 6The company maintained a strong balance sheet with cash and cash equivalents increasing by 18% to $856.4 million.
  • 7Despite the COVID-19 pandemic, the company has not identified material impairments or adverse effects to date, though it acknowledges ongoing uncertainty.

Frequently Asked Questions